Drugs / ARQ-154
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07340216 | Dec 2025 → Apr 2026 | psoriasis | Arcutis Biotherapeutics, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2020-12-09 | Arcutis Biotherapeutics, Inc. | Results Arcutis Highlights Advanced Pipeline & Unique Immuno-Dermatology Drug Development Capabilities at Virtual Investor Day on December 9, 2020 arcutis.com ↗
Psoriasis Scalp Investigator Global Assessment (S-IGA) success at 8 weeks similar to high potency steroids; |
| 2020-11-23 | Arcutis Biotherapeutics, Inc. | Results Arcutis Announces Positive Topline Data from Phase 2b Study of ARQ-154 (Topical Roflumilast Foam) as a Potential Treatment for Scalp and Body Psoriasis arcutis.com ↗
Roflumilast foam 0.3% administered once daily for 8 weeks demonstrated statistically significant improvements compared to a matching vehicle foam on key efficacy endpoints in 304 adult and adolescent patients with plaque psoriasis that included plaques on the scalp. |
All press releases naming this drug 9 releases
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ARQ-154 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07340216 ↗ |